checkAd
    Centessa Pharmaceuticals Aktie
    8,8700
     
    USD
    -0,89 %
    -0,0800 USD
    Letzter Kurs 02:00:00 Nasdaq
    8,8500
     
    USD
    900 STK
    Geldkurs 17.05.24
    8,8900
     
    USD
    800 STK
    Briefkurs 17.05.24
    ISIN: US1523091007 · WKN: A3CQ72 · SYM: CNTA · Großbritannien

    Neueste Nachrichten

    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
    13.05.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
    24.04.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
    23.04.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
    22.04.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
    28.03.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
    22.02.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
    09.02.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
    22.01.24 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
    13.11.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
    02.11.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
    31.10.23 · globenewswire · Centessa Pharmaceuticals
    Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
    30.10.23 · globenewswire · Centessa Pharmaceuticals